Tags

Type your tag names separated by a space and hit enter

Photochemotherapy for mycosis fungoides: current status.
Australas J Dermatol. 1997 Feb; 38(1):9-11.AJ

Abstract

Phototherapy for mycosis fungoides is reviewed with particular emphasis on PUVA (psoralen ultraviolet A-range) therapy and its combination with other topical and systemic treatments. PUVA therapy has the advantages of being available in all major centres, is simple to administer, relatively inexpensive and has relatively low toxicity. Medium-term results suggest that PUVA is as effective as any of the other topical therapies for stage I disease. Its combination with alpha-interferon produces significant benefit in stage II or more advanced disease. Long-term non-melanoma skin cancer is increased with PUVA and combination PUVA usage, but melanoma is not increased. Its long-term position in comparison to other therapies with regard to morbidity, mortality and quality of life needs further evaluation.

Authors+Show Affiliations

Department of Dermatology, Royal Newcastle Hospital, New South Wales, Australia.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

9046645

Citation

Watson, A. "Photochemotherapy for Mycosis Fungoides: Current Status." The Australasian Journal of Dermatology, vol. 38, no. 1, 1997, pp. 9-11.
Watson A. Photochemotherapy for mycosis fungoides: current status. Australas J Dermatol. 1997;38(1):9-11.
Watson, A. (1997). Photochemotherapy for mycosis fungoides: current status. The Australasian Journal of Dermatology, 38(1), 9-11.
Watson A. Photochemotherapy for Mycosis Fungoides: Current Status. Australas J Dermatol. 1997;38(1):9-11. PubMed PMID: 9046645.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Photochemotherapy for mycosis fungoides: current status. A1 - Watson,A, PY - 1997/2/1/pubmed PY - 1997/2/1/medline PY - 1997/2/1/entrez SP - 9 EP - 11 JF - The Australasian journal of dermatology JO - Australas J Dermatol VL - 38 IS - 1 N2 - Phototherapy for mycosis fungoides is reviewed with particular emphasis on PUVA (psoralen ultraviolet A-range) therapy and its combination with other topical and systemic treatments. PUVA therapy has the advantages of being available in all major centres, is simple to administer, relatively inexpensive and has relatively low toxicity. Medium-term results suggest that PUVA is as effective as any of the other topical therapies for stage I disease. Its combination with alpha-interferon produces significant benefit in stage II or more advanced disease. Long-term non-melanoma skin cancer is increased with PUVA and combination PUVA usage, but melanoma is not increased. Its long-term position in comparison to other therapies with regard to morbidity, mortality and quality of life needs further evaluation. SN - 0004-8380 UR - https://www.unboundmedicine.com/medline/citation/9046645/Photochemotherapy_for_mycosis_fungoides:_current_status_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0004-8380&date=1997&volume=38&issue=1&spage=9 DB - PRIME DP - Unbound Medicine ER -